2.40 BEACON part 2, NALA, & Molecular Pathology and Next-Generation Sequencing with Dr. David Carr

Plenary Session

Vinay Prasad, MD MPH

Health, Medicine, Policy, Oncology, Science & Medicine

4.7 • 789 Ratings

🗓️ 5 March 2020

⏱️ 69 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

This week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our thoughts on what they said. We then turn to the FDA's recent approval of neratinib in combination with capecitabine for HER2-positive breast cancer, based on the phase III NALA trial. Finally, we interview Dr. David Carr, a Molecular Pathology Fellow at UC San Diego, on his work in general and, specifically, next-generation sequencing. BEACON Letters to the Editor: www.nejm.org/doi/full/10.1056/NEJMoa1908075#article_letters NALA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to Plenary Session.
0:07.0	I'm your host, Dr. Vinay Prasad.
0:10.0	I'm a practicing hematologist, oncologist, and I'm associate professor of medicine.
0:14.0	I'm interested in issues at the intersection of medicine, oncology, and health policy, and that's what you're going to get on this podcast.
0:22.2	Welcome to Season 2.
0:25.1	This week on Plenary Session, we're back.
0:27.5	We're back in the studio, and we've got a lot of fun things in store for you.
0:30.9	First off, Beacon Trial, Revisited.
0:33.3	That's Anchoraph at Abidimetinib and Satoximabymab and BRAF V-600E mutated colorectal cancer.
0:38.1	You won't want to miss this.
0:39.4	We've got the answer to one of several questions in the New England Journal of Medicine.
0:44.3	And then I'm going to talk about one of the greatest drugs of all times.
0:48.9	No, not imatinib, the second greatest drug, which is niratinib, neuratnib, the her two targeted drug that causes profuse diarrhea, that is over $10,000 a month
0:58.8	of therapy, that is universally lousy drug that has never improved a clinical endpoint
1:03.3	in the history of man.
1:05.6	That's only improved surrogate endpoints.
1:06.7	And it's back now with an approval in the metastatic space based on the NALA trial, which is a bad trial,
1:12.4	which shows how low the bar at the FDA has gone. You won't want to miss this discussion.
1:16.6	Stay tuned to plenary session.
1:19.6	But first, there's a little bit of an update.
1:23.0	The author of this book, Malignant, How Bad Policy and Bad Evidence Harm People with Cancer,
1:28.3	has bought back from the publisher the audio rights to the book.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.